Manufacturing Operations Divestment Expertise
Are you looking to divest surplus R&D and manufacturing operations?
Having advised on the strategic direction of over 40 sites globally, we can help you to divest your manufacturing operations whilst safeguarding security of supply and retaining jobs, and assisting the new owners to build and grow profitable new businesses.
Our strategic reviews of operations have enabled our clients to engage us in the successful divestment of sites covering both small molecule and biologics capabilities across the globe.
Dedicated Advisors
Jansen Jacob
Vice President
Phone: +44 (0) 7951 205 420
divest@pharmaventures.com
+44 (0) 1865 332 700
Expertise and knowledge
Top tier pharmaceutical companies, biotechs, and private equity houses have trusted us to support their manufacturing operations divestment activities using our:
- in-depth knowledge of biopharmaceutical manufacturing
- personal contacts with the key players engaged in M&A, which places us in a unique position to support our clients in buying and/or selling R&D and manufacturing operations
- proven processes to ensure effective divestments at best value and in a timely manner
- globally experienced deal making team composed of senior executives from big pharma R&D, BD, management and marketing, complemented by VCs and investment bankers
Companies who have benefitted from our divestment expertise include Novartis, Sanofi, Transgene, UCB and Merck.
Our Case Studies
How can we help you?
PharmaVentures offers a comprehensive solution for biopharma companies covering R&D and primary/secondary manufacturing operations.
We can support you with strategic advice and successful transactions for your company:
Pre-deal valuation analysis and divestment strategy development
Documentation preparation and comprehensive global buyer search
Evaluation of potential buyers, including conducting relevant diligence
Management of an auction-type sale process to maximise deal value
Deal structuring advice, including negotiation support
Discretion to minimise impact on internal operations as well as external news flow
All FCA regulated activities are delivered through PharmaVentures Capital Limited, which is authorised and regulated by the Financial Conduct Authority (741356). PharmaVentures Capital Limited is a wholly owned subsidiary of Pharma Ventures Ltd. Past performance is not a guarantee of future performance. Information contained herein is for illustrative purposes only and should not be relied upon.
What Our Clients Say
“We hired PharmaVentures when our management team decided that as a matter of urgency, we needed to identify and secure products to replace a product line in the short term. Within a two-months-period, the excellent team at PV identified more than 60 product opportunities for us and initiated CDA’s and first contacts with the most interesting of them”
Senior Executive
Multinational Pharmaceutical Company